Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JMT101 combined with osimertinib in EGFR exon 20 insertion-mutant advanced or metastatic non-small cell lung cancer
CTR20212469Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Dec 2021; status: active.
02
Drugs
becotatugosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212469.